Abstract
Because human infections by Scedosporium prolificans are difficult to treat and show a very poor outcome, new therapeutic strategies are needed. Liposomal amphotericin B (LAMB) (40 mg/kg/day) increased significantly the mean survival time in immunosuppressed mice compared with a control group (22.6 vs. 8.8 days). Amphotericin B deoxycholate (1.5 mg/kg/day) and granulocyte colony-stimulating factor (G-CSF) (300 microg/kg/day) were ineffective. The combination of LAMB (40 mg/kg/day) and G-CSF (150 or 300 microg/kg/day) did not improve the results obtained with LAMB alone.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Drug Therapy, Combination
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Immunocompromised Host
-
Liposomes
-
Lymphocyte Count
-
Male
-
Mice
-
Mice, Inbred Strains
-
Mycetoma / drug therapy*
-
Scedosporium*
Substances
-
Antifungal Agents
-
Liposomes
-
liposomal amphotericin B
-
Granulocyte Colony-Stimulating Factor
-
Amphotericin B